Ignite Creation Date:
2025-12-24 @ 10:44 PM
Ignite Modification Date:
2025-12-28 @ 8:47 AM
Study NCT ID:
NCT06015035
Status:
COMPLETED
Last Update Posted:
2023-08-29
First Post:
2023-08-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Sponsor:
Tang-Du Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-04-01
Start Date Type:
ACTUAL
Primary Completion Date:
2022-04-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-04-01
Completion Date Type:
ACTUAL
First Submit Date:
2023-08-17
First Submit QC Date:
None
Study First Post Date:
2023-08-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-08-27
Last Update Post Date:
2023-08-29
Last Update Post Date Type:
ACTUAL